WP
ALLO icon

Woodline Partners’s Allogene Therapeutics ALLO Stock Holding History

Woodline Partners’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.36M Buy
4,500,624
+999,546
+29% +$2.2M 0.03% 552
2026
Q1 		$8.54M Buy
3,501,078
+579
+0% +$1.16K 0.03% 550
2025
Q4 		$4.8M Sell
3,500,499
-860,109
-20% -$1.13M 0.02% 630
2025
Q3 		$5.41M Hold
4,360,608
– – 0.03% 547
2025
Q2 		$4.93M Hold
4,360,608
– – 0.03% 560
2025
Q1 		$6.37M Buy
4,360,608
+376
+0% +$709 0.04% 445
2024
Q4 		$9.29M Sell
4,360,232
-4,068
-0.1% -$10K 0.06% 361
2024
Q3 		$12.2M Buy
4,364,300
+5,311
+0.1% +$14.2K 0.1% 266
2024
Q2 		$10.2M Buy
4,358,989
+1,725,013
+65% +$5.09M 0.1% 246
2024
Q1 		$11.8M Buy
2,633,976
+56,476
+2% +$236K 0.11% 237
2023
Q4 		$8.27M Sell
2,577,500
-2,736,415
-51% -$7.76M 0.09% 250
2023
Q3 		$16.8M Buy
5,313,915
+415
+0% +$1.82K 0.2% 152
2023
Q2 		$26.4M Buy
5,313,500
+3,121,070
+142% +$16.9M 0.31% 94
2023
Q1 		$10.8M Sell
2,192,430
-729,032
-25% -$4.68M 0.15% 187
2022
Q4 		$18.4M Sell
2,921,462
-1,604,960
-35% -$14.9M 0.25% 125
2022
Q3 		$48.9M Sell
4,526,422
-1,333,257
-23% -$18.1M 0.68% 26
2022
Q2 		$66.8M Buy
5,859,679
+5,427,529
+1,256% +$48.2M 1.03% 8
2022
Q1 		$3.94M Sell
432,150
-67,945
-14% -$708K 0.06% 271
2021
Q4 		$7.46M Sell
500,095
-312,635
-38% -$5.52M 0.11% 234
2021
Q3 		$20.9M Buy
812,730
+127,975
+19% +$3.04M 0.34% 79
2021
Q2 		$17.9M Buy
684,755
+12,111
+2% +$345K 0.33% 81
2021
Q1 		$23.7M Buy
672,644
+105,105
+19% +$3.55M 0.53% 59
2020
Q4 		$14.3M Buy
567,539
+167,306
+42% +$5.45M 0.38% 83
2020
Q3 		$15.1M Buy
400,233
+271,605
+211% +$10.2M 0.49% 57
2020
Q2 		$5.51M Buy
+128,628
New +$4.65M 0.22% 106

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners's ALLO Position: Q2 2026 in Review

Woodline Partners increased its Allogene Therapeutics (ALLO) stake by 29% in Q2 2026, buying an estimated $2.2M and bringing the position to 4,500,624 shares worth $9.36M. The position accounts for 0.03% of the portfolio, ranked #552.

Woodline Partners first reported a position in ALLO in Q2 2020 and has held it in 25 quarters since. The position peaked at $66.8M in Q2 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Woodline Partners held 4,500,624 shares of Allogene Therapeutics worth $9.36M as of Q2 2026.
  • Woodline Partners bought 999,546 Allogene Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Allogene Therapeutics made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #552 holding.
  • Woodline Partners first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Woodline Partners's Allogene Therapeutics position peaked at $66.8M in Q2 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.